Home

Differential
Counter

Flow
Tutorial

 

  
 
Myeloproliferative
neoplasms		 Neoplasms with eosinophilia
(PDGRA/PDGFRB/FGFR1)		 MDS/MPN MDS AML Acute leukemia
ambiguous lineage
Precursor lymphoid
neoplasms		 Mature B cell
neoplasms		 Mature T and NK
neoplasms		 Hodgkin
lymphoma		 Immunodeficiency associated
lymphoproliferative disorders		 Histiocytic and dendritic
cell neoplasms
 

Diffuse Large B Cell Lymphoma
  Unusual antigen expression abstracts Prognostic abstracts Cytogenetic abstracts Antigen chart
CLL/SLL
 B cell prolymphocytic leukemia
Splenic B cell marginal zone lymphoma
Hairy cell leukemia
Splenic B cell lymphoma / leukemia
Lymphoplasmacytic lymphoma
Heavy chain disease
Plasma cell neoplasms
Extranodal marginal zone lymphoma of mucosa associated lymphoid tissue
Nodal marginal zone lymphoma
Follicular lymphoma
Primary cutaneous follicle center lymhoma
Mantle cell lymphoma
Diffuse large B cell lymphoma
DLBCL associated with chronic inflammation
Lymphomatoid granulomatosis
Primary mediastinal large B cell lymphoma
Intravascular large B cell lymphoma
ALK positive large B cell lymphoma
Plasmablastic lymphoma
Large B cell lymphoma - HHV8 associated multicentric Castleman
Primary effusion lymphoma
Burkitt lymphoma
B cell lymphoma, unclassifiable with features of DLBCL and Burkitt
B cell lymphoma, unclassifiable with features of DLBCL and Hodgkin
Article Notes
Miscellaneous studies
Germinal cell (favorable) versus Non-germinal center cell or activated (unfavorable) types
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. CD10, bcl-6, MUM1, FOXP1, cyclin D2, and bcl-2
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Bcl-6, Bcl-2, CD10, MUM-1
Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. CD10, bcl6, MUM1/IRF4, bcl2, Ki67, and CD21 / BCL2, BCL6, and MYC (FISH)
Individual markers associated with less aggressive disease
Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Bcl-6 (IHC and PCR)
CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses. CD10, Bcl-2
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Bcl-6, Bcl-2
High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. Bcl-6 expression compared with promoter region mutations
Individual markers associated with more aggressive disease
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Bcl-2, Bcl-6, CD10
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Bcl-2
Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma. Bcl-2 predictor stratified to R-CHOP and CHOP alone
Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Cell size
The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. EBER